RAD51, a key protein that mediates the homologous recombination repair pathway after DNA DSBs, is reportedly associated with low survival rates, high risk of tumor relapse, distant metastases, and chemotherapy resistance in breast cancer, lung cancer, brain cancer, and others (Laurini, et al. 2020; Lee, et al. 2019). This evidence concerns the gene RAD51 and neoplasm.